Selank: A Research Overview

Selank is a synthetic heptapeptide representing a fundamentally different class of anxiolytic compound from benzodiazepines. Its unique GABAergic potentiation mechanism — without sedation, cognitive impairment, or withdrawal — makes it a compound of significant interest in neuroscience and psychiatric research.

What is Selank?

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide analogue of the immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), developed at the Russian Academy of Sciences' Institute of Molecular Genetics (IMG). First synthesised in the 1990s by Professor V. K. Uteshev's laboratory, Selank was registered as an approved pharmaceutical in Russia in 2009 for the treatment of anxiety disorders, neurasthenia, and cognitive impairment associated with asthenic conditions.

The peptide's unique structure — a tuftsin analogue with a C-terminal Pro-Gly-Pro extension that enhances metabolic stability — combines anxiolytic, nootropic, and immunomodulatory properties in a single molecule. Unlike benzodiazepines, preclinical research demonstrates anxiolytic effects without sedation, muscle relaxation, cognitive impairment, or withdrawal syndrome.

Known Mechanism of Action

GABAergic Potentiation (Non-Benzodiazepine Site)

Selank's primary anxiolytic mechanism involves potentiation of the GABAergic system through enhancement of GABA-A receptor function. Critically, this enhancement occurs via an allosteric mechanism distinct from the benzodiazepine binding site — explaining the notable absence of sedation, tolerance, and physical dependence. Radioligand binding studies confirm that Selank does not displace [³H]flunitrazepam from the benzodiazepine site, yet potentiates GABA-induced chloride currents at GABA-A receptors in cultured cortical neurons.

Dopaminergic and Serotonergic Modulation

Published microdialysis studies in rats demonstrate that Selank modulates extracellular dopamine and serotonin levels in the prefrontal cortex, nucleus accumbens, and striatum. The effect is bidirectional — normalising elevated monoamine levels in stressed animals without significantly altering baseline levels in unstressed controls. This is consistent with an anxiolytic that reduces stress-induced neurotransmitter dysregulation rather than imposing a fixed pharmacological effect.

BDNF and Enkephalin Upregulation

Selank upregulates BDNF expression in the hippocampus and prefrontal cortex — a finding associated with long-term neuroplastic adaptations rather than acute anxiolysis. Additionally, Selank inhibits enkephalin-degrading enzymes (including neprilysin and aminopeptidase N), thereby prolonging endogenous opioid tone — a pathway that may contribute to its anxiolytic and stress-protective profile.

Immunomodulatory Activity

As a tuftsin analogue, Selank retains immunomodulatory properties. Research demonstrates modulation of IL-1β, IL-6, and TNF-α production in peripheral blood mononuclear cells, as well as enhancement of NK cell activity. This dual anxiolytic-immunomodulatory profile is particularly relevant for stress-related immunological research.

Preclinical Research Data

• Elevated Plus Maze: Selank (0.1–1.0 mg/kg intranasal) produces dose-dependent increases in open arm time and entries — the gold standard preclinical measure of anxiolysis — without affecting total locomotion.
• Social Interaction Test: Selank reverses stress-induced reductions in social interaction time in rats, demonstrating efficacy in ethologically-relevant anxiety models.
• Conditioned Defensive Burying: Selank reduces burying behaviour without impairing motor function — an important distinction from benzodiazepines which reduce burying only at doses that produce ataxia.
• Withdrawal Studies: Chronic Selank administration followed by abrupt discontinuation produces no behavioural signs of withdrawal (anxiety-like behaviour on EPM, seizure susceptibility, weight loss) — in marked contrast to benzodiazepines.

Research Protocols & Dosing

Rodent studies typically use 0.1–1.0 mg/kg intranasally for anxiolytic models, and 200–800 µg/kg/day for immunomodulation research. Selank is typically administered intranasally (the peptide reaches the CNS via olfactory epithelium transport, bypassing the blood-brain barrier). Subcutaneous administration at 100–500 µg/kg is also documented in the literature for systemic studies.

Stability & Handling

Selank is stable as a lyophilized powder at 2–8°C (refrigerated) for 12+ months. Once reconstituted with bacteriostatic water, it remains stable for 7–14 days at 2–8°C. Selank is readily soluble in water and saline. Avoid freeze-thaw cycles and protect from light.

---